WEGOVY® FLEXTOUCH® 0.25mg (Italian)

Description

Name: WEGOVY® FLEXTOUCH® 0.5mg (Italian)
Manufacturer: NOVO NORDISK
Active Substance(s): SEMAGLUTIDE
Strength: 0.25mg
Pack Size: 1 Pen, 4 disposable NovoFine Plus needles

WEGOVY® FLEXTOUCH® 0.25mg is the starting dose of semaglutide in a once-weekly injection regimen for chronic weight management. This formulation initiates patient acclimatization to the GLP-1 receptor agonist and helps minimize gastrointestinal side effects as the dosage gradually increases over time.

This dose is used during the first 4 weeks of treatment to begin therapeutic titration. It is not intended for weight maintenance but is essential for establishing patient tolerance.

Key Features:

• Contains 0.25mg semaglutide in 0.5mL pre-filled pen

• Initiates week 1–4 of the dose-escalation protocol

• Designed to minimize nausea and vomiting in early treatment

WEGOVY® 0.25mg is delivered in a pre-filled, single-dose FlexTouch® pen, color-coded and labeled for easy differentiation from higher doses in the titration sequence. It’s ready-to-use and designed for subcutaneous self-administration with no need for reconstitution or priming.

Each package includes:

• 4 pre-filled pens, covering 4 weeks of therapy

• Each pen contains 0.5mL of solution delivering 0.25mg of semaglutide

• Pens are designed for once-weekly single use

Ingredients per dose:

• Semaglutide 0.25mg

• Disodium phosphate dihydrate, sodium chloride

• Hydrochloric acid/sodium hydroxide (for pH adjustment)

• Water for injections

• Free from preservatives, latex, or animal proteins

WEGOVY® 0.25mg is indicated as the initial step in semaglutide therapy for chronic weight management, always in conjunction with calorie restriction and increased physical activity. It is not a therapeutic or maintenance dose but an essential priming stage to improve tolerability.

Indications:

• Adults with BMI ≥30 kg/m²

• Adults with BMI ≥27 kg/m² with weight-related comorbidities:

  • Type 2 diabetes

  • Hypertension

  • Dyslipidemia

  • Obstructive sleep apnea

Contraindications:

• Hypersensitivity to semaglutide or excipients

• History of medullary thyroid carcinoma (MTC) or MEN 2

• Pregnant or breastfeeding individuals

• Not suitable for pediatric use

Common Side Effects:

• Nausea, vomiting, constipation, diarrhea

• Headache, fatigue, abdominal pain

• Injection site reactions (redness, itching, or swelling)

Less Common/Serious Effects:

• Gallbladder disease (e.g. cholelithiasis)

• Pancreatitis

• Hypoglycemia, especially if used with insulin or sulfonylureas

WEGOVY® 0.25mg is administered via subcutaneous injection once per week on the same day, at any time of day, with or without food. The injection should be performed in the abdomen, thigh, or upper arm using the FlexTouch® pen.

Administration Protocol:

• Use 0.25mg dose for weeks 1–4

• Followed by stepwise increase to 0.5mg, 1.0mg, 1.7mg, and 2.4mg

• Inject in the subcutaneous tissue, avoiding intramuscular or intravenous routes

• Rotate injection sites weekly to avoid irritation

• Each pen is single-use only; discard after injection

Storage Guidelines:

• Store pens in refrigerator at 2°C–8°C

• After removal, pens may be stored at room temperature (≤30°C) for up to 6 weeks

• Do not freeze; discard if frozen

• Keep pens in original carton to protect from light exposure

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.